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INTRODUCTION 
The oral route of administration is preferred to be the most 
convenient route due to its manifold advantages including self 
administration, compactness, easy manufacturing, ease of 
ingestion, avoidance of pain, adaptability and most importantly 
patient compliance [1]. Maximum therapeutically active 
substances are present in the form of tablet, capsule, and pill or 
powder for oral administration. These dosage forms are to be 
swallowed so that the pharmaceutically active substance can be 
absorbed via the gastrointestinal tract. Among all other oral 
solid dosage forms tablet hold the premier position due to its 
above mentioned convenience. Some times the administration 
of tablet and capsules with a glass of water become 
inconvenient or impractical for some patients, particularly 
pediatric and geriatric patients find difficulty in swallowing or 
chewing solid dosage forms [1, 2]. Many patients are unwilling 
to take these solid preparations due to fear of choking [3]. The 
administration problem is also allied with number of medical 
conditions including stroke, Parkinsonism and other 
neurological disorders [1]. Immediate Release Drug Delivery 
System (IRDDS) has acquired an important position in the 
market by overcoming previously encountered administration 
problems. IRDDS has the unique property of rapidly 
disintegrating or dispersing and releasing the drugs as soon as 
they come in contact with the saliva, thus obviating the 
requirement of water during administration [4].  
The drug of interest in the present research venture is 
Salbutamol Sulphate, a freely water-soluble Beta-receptor 
agonist widely used as bronchodilator to relieve acute as well 
as chronic attacks of asthma and the reversible element of 
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airways obstruction commonly found in Chronic Obstructive 
Pulmonary Disease (COPD)
 
[5, 6]. Among the β2-adrenoceptor 
agonists Salbutamol Sulphate is the most preferred drug.  
Drug substances are classified according to Biopharmaceutics 
Classification System in four distinct categories, depending on 
the basis of permeability and solubility of the drug molecule, 
which are as follows- 
Class I - High Permeability, High Solubility 
Class II - High Permeability, Low Solubility 
Class III - Low Permeability, High Solubility 
Class IV - Low Permeability, Low Solubility [7, 8] 
 
Salbutamol Sulphate, the therapeutic moiety of this study 
comes under Class III, suggesting that it is highly soluble but 
less permeable. The oral bioavailability depends upon the 
drugs’ permeability, and the oral bioavailability of Salbutamol 
Sulphate is 71 ± 9%, which indicates that it is less permeable. 
Because, according to BCS, a drug substance will be 
considered as highly permeable when the extent of absorption 
in humans is determined to be more than 90% of an oral dose 
[7]. Beside this 1 gm of Salbutamol Sulphate effortlessly 
dissolves in less than 10 ml of water, thus it can be considered 
as freely soluble and enlisted in BCS Class III scheduled drugs.  
The objective of the present study was to formulate and 
investigate the influence of different diluents, disintegrants and 
its different concentrations on the release of Salbutamol 
Sulphate and other physicochemical parameters of the 
formulated tablets. 
 
MATERIALS & METHODS 
Salbutamol Sulphate IP, (98.04% w/v) was obtained as a gift 
sample from Inga Laboratories (Mumbai). Sodium Starch 
Glycolate (Extra pure) was procured from Loba Chemie Pvt. 
Ltd. (Mumbai), micro crystalline cellulose, talc, magnesium 
stearate, mannitol were AR grade, obtained from S.D. Fine- 
Chem. Limited (Mumbai) and used as such.                   
 
Preparation of tablets 
All the ingredients were screened through a sieve (#60). 
Required amount of Salbutamol Sulphate equivalent to 4 mg of 
Salbutamol was then mixed thoroughly with diluents (mannitol, 
lactose) for 5 minutes in the formulations as designed in Table-
1 and Table-2. There are several batches without drug. To the 
above mixture superdisintegrant (sodium starch glycolate, 
micro crystalline cellulose) was added and again mixed for 5 
minutes. Then lubricants (magnesium Stearate and talc) were 
passed through the sieve and added to the above blend and 
again mixed for another 2 minutes. The mixed blend was 
compressed using 10 station rotary tablet punching machine 
(Rimek Minipress I, Ahmedabad) producing biconcave tablets 
of 6 mm diameter and weighing around 110 mg. a total of 20 
batches of tablets were made containing 100 tablets in each 
batch and hardness was kept around 4 kg/cm
2
. 
 
Evaluation of IRTs 
All the batches of prepared IRT were evaluated for weight 
variation, friability, drug content uniformity and disintegration 
time. In vitro dissolution studies were also performed for the 
selected batches. 
Determination of Thickness and Diameter of the tablets 
Thickness and diameter of five randomly selected tablets from 
each batch were measured with a Slide Calipers. Then the 
average diameter, thickness and standard deviation were 
calculated.  
Weight Variation Test  
A random sample of 20 tablets was taken and total as well as 
individual weights were recorded. Average weight was 
calculated and deviation of individual tablet weight from 
average weight was calculated. Theoretically the weight of the 
tablets should be within ±7.5% of the tablet weight [10]. 
Wetting time 
Wetting time of dosage form is related with the contact angle. 
Wetting time of the IRT is another important parameter, which 
needs to be assessed to give an insight into the disintegration 
properties of the tablets; a lower wetting time implies a quicker 
disintegration of the tablet. The wetting time of the tablets can 
be measured using a simple procedure. Five circular tissue 
papers of 6 cm diameter are placed in a petridish with a 6 cm 
diameter. 10 ml of water-containing Eosin, a water-soluble dye, 
is added to petridish. A tablet is carefully placed on the surface 
of the tissue paper. The time required for water to reach upper 
surface of the tablet is noted as a wetting time [2].  
Friability 
A sample of 20 tablets were taken and dedusted carefully prior 
to testing. The tablets were placed in the drum of friability 
tester and rotated for 100 times at the speed of 25 rpm (Roche 
friabilator). Then the tablets were removed, dedusted and 
accurately weighed. The friability is expressed as the loss of 
mass and it is calculated as a percentage of the initial mass 
[10]. 
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Disintegration time 
One tablet was placed in each of the six tubes of the basket and 
apparatus was operated using water maintained at 37°± 1° C as 
immersion fluid. The time of disintegration of all tablets with 
no palpable mass remaining in the tube was noted [10].  
Fourier Transformed Infrared Study 
Fourier Transformed Infrared (FT-IR) spectrum (FTIR-8400S, 
Shimadju, Japan) of Salbutamol Sulphate and the formulations 
(F3 and F8), which were grinded separately and mixed with 
dried and ground potassium bromide (FT-IR grade) at 1:100 
ratio, pelletized at 10-ton pressure by using potassium bromide 
press. Then the prepared pellets were scanned and the spectrum 
was recorded between 4000–400 cm–1 using a high-energy 
helium neon laser source and DLATGS (L-alanine-doped 
deuterated triglycine sulphate) detector. Finally the spectrum 
was analyzed by using the IR Solution software (version 1.30 
by Shimadju Corporation, Japan). 
Dissolution test [10, 11]
 
In-vitro dissolution studies of the formulations F1-F10 were 
carried out using USP Dissolution Apparatus II (Veego, VDA-
8DR USP Standard), 900 ml of phosphate buffer solution pH 
6.8 was used as dissolution medium at 37°± 0.5° C at 50 rpm 
for 30 minutes. 5 ml of aliquots was withdrawn at 
predetermined intervals by maintaining sink condition. Finally 
the solution was filtered and analyzed by U.V. Visible 
spectrophotometer (Shimadzu, UV-1700 Pharmaspec) at 276 
nm. 
 
Table-1: Composition of different formulations 
Ingredients (%) DM1 DM2 DM3 DM4 DM5 DL1 DL2 DL3 DL4 DL5 
Salbutamol Sulphate  - - - 4.46 4.46 - - - 4.46 4.46 
Starch 3 3 3 3 3 3 3 3 3 3 
Sodium Starch Glycolate - 5 - 5 - - 5 - 5 - 
Micro Crystalline Cellulose - - 5 - 5 - - 5 - 5 
Talc 1 1 1 1 1 1 1 1 1 1 
Magnesium Stearate 1 1 1 1 1 1 1 1 1 1 
Lactose - - - - - qs qs qs qs qs 
Mannitol qs qs qs qs qs - - - - - 
 
Table-2: Composition of different formulations of different type and concentration of superdisintegrant 
INGREDIENTS (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Salbutamol Sulphate 4.46 4.46 4.46 4.46 4.46 4.46 4.46 4.46 4.46 4.46 
Starch 3 3 3 3 3 3 3 3 3 3 
Sodium Starch Glycolate 2.5 5 10 15 20 - - - - - 
Micro Crystalline Cellulose - - - - - 2.5 5 10 15 20 
Talc 1 1 1 1 1 1 1 1 1 1 
Magnesium Stearate 1 1 1 1 1 1 1 1 1 1 
Mannitol qs qs qs qs qs qs qs qs qs qs 
 
Kinetic Treatment 
To elucidate kinetics of drug release from the prepared IRTs, 
cumulative percentage of drug release and cumulative 
percentage of drug remained was plotted as the function of time 
(t) different release model. Peppas and Korsmeyer equation 
was used to determine the mechanism of rate of release of drug. 
The ‘n’ value in Peppas and Korsmeyer equation represents 
diffusional exponent, if it is less than 0.5, diffusion is the major 
driving force, and is normally said to follow Fickian diffusion 
and when ‘n’ is more than 0.5, the drug release is mainly 
controlled by degradation and follows non-Fickian or 
anomalous release [12]. 
 
RESULTS& DISCUSSIONS  
The compositions of various formulations were prepared by 
direct compression were shown in and Table-1 and Table-2 
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respectively and evaluated for different physicochemical 
parameters. Weight variation, friability, wetting time of the 
prepared batches of the tablets were complied with official 
limits and shown in Table-3. Other physical parameters such as 
diameter and thickness of the tablets were also presented in the 
same table. 
Choice of diluents and superdisintegrants in the formulation 
development of an effective IRDDS is largely depending upon 
the governing factors such as wetting time and disintegration 
time. Mannitol, lactose as diluents and sodium starch glycolate, 
micro crystalline cellulose as superdisintegrants were 
experimented in these protocols (DM1-DM5 and DL1-DL5). 
Among different combinations tried, the combination of 
mannitol with sodium starch glycolate (DM4) as well as 
mannitol with micro crystalline cellulose (DM5) showed better 
result, because of low disintegration time (54.66 ±5.46 s, 65.66 
±5.46 s) and wetting time (27.33 ±2.73 s, 33.16 ±2.85 s) 
respectively. Mannitol is a good diluent for direct compression 
in the formulation of IRT because it is a directly compressible 
sugar with a sweet taste that aids in taste masking also and it 
gives a cooling sensation in the mouth due to its negative heat 
of solution.  
 
Table-3: Different physical parameters evaluated of the prepared batches. 
Batch 
Mean ± SD 
Diameter 
a 
(mm) 
Thickness 
a
 
(mm) 
Weight 
b 
(mg) 
% Friability 
Wetting time 
(sec) 
c
 
Disintegration 
time (sec) 
c
 
DM1 6.22±0.04 3.74±0.05 110.05±2.41 0.347 62.33±4.36 123.66±8.61 
DM2 6.24±0.05 3.82±0.04 109.45±2.92 0.359 30.83±3.31 62.16±6.794 
DM3 6.22±0.08 3.72±0.04 108.9±1.94 0.402 30.66±2.33 61.83±4.83 
DM4 6.20±0.07 3.82±0.08 111.5±2.50 0.405 27.33±2.73 54.66±5.46 
DM5 6.22±0.08 3.86±0.05 110.7±1.83 0.364 33.16±2.85 65.66±5.46 
DL1 6.24±0.09 3.78±0.08 111.2±2.16 0.268 64.16±4.44 127.33±7.44 
DL2 6.28±0.04 3.82±0.04 110.8±2.31 0.393 32.83±3.92 64.33±5.95 
DL3 6.16±0.05 3.86±0.05 108.9±2.62 0.591 33.83±2.92 66.16±7.33 
DL4 6.24±0.05 3.78±0.04 110.9±2.63 0.357 31.66±3.44 65.33±9.13 
DL5 6.22±0.04 3.8±0.07 110.95±2.76 0.352 35.83±3.54 71.83±7.08 
a: n =10  b: n = 20  c: n = 6 
 
Fourier Transformed Infrared Study 
FT-IR studies at 150 scan and at resolution of 1cm
-1
 were 
recorded and presented in Fig No-1, for over laid spectra of 
Salbutamol Sulphate and formulation F3 and in Fig No-2, for 
overlaid spectra of the drug and formulation F8.In FT-IR 
studies the characteristic C
__
N stretching at around 1258 cm
–1 
and C
__
H aromatic bending at around 839 cm
–1 
were clearly 
distinguishable in Salbutamol Sulphate loaded Immediate 
Release Tablet [13]. Additionally O
__
H bending of Salbutamol 
Sulphate at around 1080 cm
–1 
as well as C
__
H aromatic bending 
at around 881 cm
–1 
in both the formulations as well as in the 
drug powder suggesting no drug-excipients chemical 
interactions as such. The FT-IR studies thus indicated that the 
model drug Salbutamol Sulphate was entrapped in unbound 
amorphous form. In the next step, different formulations (F1-
F10) were further prepared and evaluated to select and 
optimize the concentration of super disintegrant between 
sodium starch glycolate and micro crystalline cellulose (Table-
2), keeping all other parameters constant. Micro crystalline 
cellulose is mainly used as filler in the preparation of tablets, 
but it is also used as a disintegrant at low concentration. Thus 
batches were prepared with the microcrystalline cellulose in 
different concentration as like sodium starch glycolate. All the 
prepared batches showed almost similar diameter (6.18-6.28 
mm) and thickness (3.78-3.84 mm). Friability of all the 
formulations was found within the official limit. Formulation 
F4 represents the lowest wetting time and disintegration time 
(17.66 ±1.36 and19.83 s ±1.83 s respectively) which indicates a 
better result among the prepared batches, on the basis of these 
two governing parameters. These two time parameters helps to 
point out that, with further increase in the disintegrant 
concentration, the disintegration time may not reduce or this is 
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the optimum concentration of the specific disintegrant beyond 
which the disintegration time may not reduce significantly 
because these two physical parameters are the sensitive tools 
for pharmaceutical development of IRDDS. 
 
Fig-1. FT-IR overlaid spectra of Salbutamol Sulphate (
_____
) and Salbutamol Sulphate loaded formulation (F3) (
_____
). 
 
Fig-2. FT-IR overlaid spectra of Salbutamol Sulphate (
_____
) and Salbutamol Sulphate loaded formulation (F8) (
_____
). 
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Table-4: Different evaluation parameters of the prepared batches. 
Batch 
Mean ± SD Cumulative % 
release after 
15 minutes 
Diameter 
a 
(mm) 
Thickness 
a
 
(mm) 
Weight 
b 
(mg) 
% 
Friability 
Wetting 
time (sec) 
c
 
Disintegration 
time (sec) 
c
 
F1 6.24±0.08 3.82±0.08 110.5±2.64 0.316 25.33±2.16 80.33±5.12 86.36 
F2 6.22±0.08 3.84±0.05 109.7±2.31 0.364 23.16±2.13 53.66±2.25 89.11 
F3 6.26±0.05 3.84±0.05 109.25±2.48 0.405 21.16±1.16 36.66±2.06 89.37 
F4 6.28±0.04 3.82±0.11 110.65±2.25 0.362 17.66±1.36 19.83±1.83 93.29 
F5 6.18±0.08 3.82±0.08 110.2±2.52 0.363 19.16±1.94 21.16±2.04 93.99 
F6 6.18±0.08 3.78±0.08 110.1±2.55 0.451 37.33±2.42 88.66±3.14 78.65 
F7 6.24±0.05 3.84±0.09 110.5±2.25 0.637 34.5±2.16 55.83±2.48 80.54 
F8 6.26±0.11 3.78±0.08 109.75±2.22 0.405 25.33±1.96 50.16±2.63 85.71 
F9 6.22±0.11 3.78±0.08 110.75±2.76 0.407 25.16±2.13 25.83±1.94 93.04 
F10 6.18±0.04 3.82±0.08 109.95±2.43 0.541 28.66±2.80 25.33±3.07 91.75 
a: n =10  b: n = 20  c: n = 6 
 
More than 78% of drug released within 15 minutes. F4, F5, F9 
and F10 these formulations releases more than 91% of drug 
within 15 minutes. Though F4, F5 and F9 releases almost 
similar amount of drug but based on the wetting time and in-
vitro disintegration time F4 was taken as the best formulation 
among all the formulations. 
When treated with the first order and zero order kinetics it was 
observed that all the formulations followed first order kinetics 
except F3 and F7, which followed zero order kinetics, as 
evident from regression coefficient values. The finally selected 
formulation F4 was evidently following swelling controlled, 
first order-Fickian diffusion release kinetic [14, 15]. 
Overall results suggest that IRT of Salbutamol Sulphate can be 
prepared successfully and 15% disintegrant concentration is 
suitable for the preparation of Salbutamol Sulphate IRT as well 
as tablets containing sodium starch glycolate is the best.  
 
CONCLUSION 
This article demonstrate recent advances in formulation 
development and processing technologies need the effort to 
achieve more sophisticated drug delivery system. 
The present study was carried out to meet the forgoing dialogue 
regarding the idea that Class III (high-solubility, low-
permeability) compounds should also be eligible for a 
biowaiver as well as to improve patient compliance. The 
present invention is a rapid orally disintegrating pharmaceutical 
solid dosage form for water soluble but less permeable 
pharmaceutically active ingredient, combined with 
conventional pharmaceutical excipients and compressed into a 
tablet by using conventional pharmaceutical tabletting 
techniques. The use of organoleptically pleasing ingredients 
such as mannitol (mannitol has a negative heat of solution 
which further adds to the organoleptically pleasing nature of 
the formation); one obtains a dosage form which rapidly 
disintegrates and forms a watery slurry which is much more 
organoleptically pleasing and very easy to swallow. 
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